ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Files An 8-K Other Events

Item8.01

Attached hereto as Exhibit 99.1 is a press release issued by
OncoGenex Pharmaceuticals, Inc. (OncoGenex) on June13, 2017
announcing that the special meeting of OncoGenex stockholders to
vote on the proposed merger with Achieve Life Science, Inc.
(Achieve) and related matters will be held on August1, 2017, at
9:00 a.m. Pacific Time, at 1191 Second Avenue, Floor 10, Seattle,
Washington, 98101. OncoGenex stockholders of record as of the
close of business on June13, 2017 are entitled to vote at the
special meeting and will receive the final proxy
statement/prospectus/information statement, which will be mailed
to stockholders beginning June19, 2017.

Reference is made to the Exhibit Index included with this Current
Report on Form 8-K.

Additional Information about the Proposed Merger

This communication is being made in respect of the proposed
merger involvingOncoGenex Pharmaceuticals, Inc.andAchieve Life
Science, Inc.OncoGenex filed a registration statement on Form S-4
(File No.333-216961) with theSEC, which contains a proxy
statement/prospectus/information statement, and plans to file
with theSECother documents regarding the proposed transaction.
The registration statement was declared effective on June13,
2017. The final proxy statement/prospectus/information statement
will be sent to the stockholders of OncoGenex and Achieve. The
final proxy statement/prospectus/information statement contains
information about OncoGenex, Achieve, the proposed merger and
related matters.STOCKHOLDERS ARE URGED TO READ THE FINAL PROXY
STATEMENT/PROSPECTUS/INFORMATION STATEMENT (INCLUDING ANY
AMENDMENTS OR SUPPLEMENTS) AND OTHER DOCUMENTS FILED WITH THE SEC
CAREFULLY IN THEIR ENTIRETY, AS THEY CONTAIN IMPORTANT
INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING A
DECISION ABOUT THE MERGER AND RELATED MATTERS.In addition to
receiving the final proxy statement/prospectus/information
statement and proxy card by mail, stockholders will also be able
to obtain the final proxy statement/prospectus/information
statement, as well as other filings containing information about
OncoGenex, without charge, from theSECswebsite
(http://www.sec.gov) or, without charge, by directing a
written request to:OncoGenex Pharmaceuticals, Inc.,19820 North
Creek Parkway,Suite 201, Bothell, WA98011, Attention: Investor
Relations or toAchieve Life Science, Inc.,30 Sunnyside
Avenue,Mill Valley, CA94941, Attention:Rick Stewart.

This communication shall not constitute an offer to sell or
the solicitation of an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offering
of securities in connection with the proposed merger shall be
made except by means of a prospectus meeting the requirements of
Section10 of the Securities Act of 1933, as amended.

Participants in Solicitation

OncoGenex and its executive officers and directors may be deemed
to be participants in the solicitation of proxies from OncoGenexs
stockholders with respect to the matters relating to the proposed
merger. Achieve and its officers and directors may also be deemed
a participant in such solicitation. Information regarding
interests that OncoGenex, Achieve and the executive officers or
directors of OncoGenex or Achieve have in the proposed merger is
set forth in the final proxy statement/prospectus/information

2

statement that OncoGenex filed with theSECon June13, 2017 in
connection with its stockholder vote on matters relating to the
proposed merger. Additional information regarding OncoGenexs
executive officers and directors is available in OncoGenexs proxy
statement on Schedule 14A, filed with theSEConApril 21, 2016.
Stockholders are able to obtain this information by reading the
final proxy statement/prospectus/information statement.

3

About ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI)

OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).